Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1671927 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $33.87Day +1.35%Mkt cap $1.7B1Y +1.1%Off 52W high −16.8%Vol (1Y) 38.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.6% of sh out |
| Days to cover12.6d |
| 13F net flow (QoQ)−1.17% |
| Top-10 13F concentration60.3% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$412.8M |
| Earnings (TTM)-$27.6M |
| ROE−9.6% |
| Net margin−8.9% |
| Sales growth 3Y31.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−2.4% |
| 1Y+1.1% |
| 3Y−48.7% |
| 5Y+3.5% |
| Since incept. (ann.)−7.2% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)38.1% |
| Ann. volatility (3Y)41.5% |
| Sharpe (1Y)0.18 |
| Sharpe (3Y)−0.33 |
| Max drawdown (1Y)−30.9% |
| Max drawdown (3Y)−67.4% |
| Beta (3Y vs SPY)0.75 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 4.9M | $147M | 9.61% | +0.0% |
| FMR LLC | 4.8M | $146M | 9.53% | +6.4% |
| WELLINGTON MANAGEMENT GROUP LLP | 4.7M | $142M | 9.28% | +0.3% |
| PRIMECAP MANAGEMENT CO/CA/ | 3.7M | $111M | 7.29% | −6.8% |
| Bellevue Group AG | 2.8M | $84M | 5.52% | +0.0% |
| Vestal Point Capital, LP | 2.8M | $83M | 5.46% | +373.0% |
| TANG CAPITAL MANAGEMENT LLC | 2.6M | $80M | 5.23% | +0.8% |
| Deep Track Capital, LP | 1.9M | $58M | 3.81% | −3.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 103.5% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 8,969,565 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.25 | +150.0% | $106.7M | +13.6% |
| 2025-12-31 | 2026-02-25 | — | — | $104.5M | +24.3% |
| 2025-09-30 | 2025-11-06 | $0.00 | −100.0% | $103.7M | +29.2% |
| 2025-06-30 | 2025-08-07 | −$0.20 | — | $98.0M | +29.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
